1. Evaluation of BCL6 and SIRT1 as Non-Invasive Diagnostic Markers of Endometriosis
- Author
-
Alison M. Sansone, Brooke V. Hisrich, R. Brandt Young, William F. Abel, Zachary Bowens, Bailey B. Blair, Avery T. Funkhouser, David P. Schammel, Lisa J. Green, Bruce A. Lessey, and Anna V. Blenda
- Subjects
endometriosis ,SIRT1 ,BCL6 ,ELISA ,non-invasive ,infertility ,Biology (General) ,QH301-705.5 - Abstract
(1) Background: Endometriosis is characterized by the presence of endometrial glands and stroma outside of the uterus and is often associated with severe pelvic pain and infertility. Our study explored the utilization of B-Cell Lymphoma 6 (BCL6) and Sirtuin 1 (SIRT1) as potential biomarkers in serum, plasma, urine, and cervical mucus for a non-invasive diagnostic test for endometriosis. BCL6 was chosen based on its previously reported elevated expression in endometrial biopsies, and SIRT1 is co-expressed and upregulated in the endometrium of women with endometriosis. (2) Methods: BCL6 and SIRT1 levels were measured using enzyme-linked immunoassay (ELISA) in samples from 20 women with endometriosis (ten with stages I/II and ten with stages III/IV) and ten women without endometriosis. (3) Results: Levels of SIRT1 in sera showed a statistically significant elevation in advanced stages III/IV compared to controls and stages I/II. No significant differences were found in other bodily fluids for SIRT1 or any bodily fluids tested for BCL6. (4) Conclusions: These results suggest some potential of SIRT1 expression within serum as a predictor of advanced asymptomatic stages of endometriosis. Using immunohistochemistry (IHC) staining and H-SCORE values for the elevated BCL6 (and potentially SIRT1) levels in endometrial biopsy samples seems to have higher diagnostic potential based on the previously published studies.
- Published
- 2021
- Full Text
- View/download PDF